News
Oct 28, 2015
CardioCell CEO Presents at BIO-Europe 2015
MUNICH, GERMANY – BIO-EUROPE 2015 – Oct. 28, 2015 – CardioCell LLC, a Stemedica Cell Technologies Inc. subsidiary that uses allogeneic stem cells for cardiovascular indications, announces a presentation by CEO Sergey Sikora, Ph.D., at BIO-Europe 2015 in Munich, Germany, Nov. 2-4. The session on Nov. 3 at 9 a.m. illustrates how CardioCell’s ischemia-tolerant mesenchymal stem cell (itMSC) therapies are being used in Phase II clinical trials for acute myocardial infarction and chronic heart failure.
|
What: |
CEO Sergey Sikora shares an overview of biotech startup CardioCell and its unique allogeneic stem cell therapies for cardiovascular indications. |
|
When: |
Tues., Nov. 3, 2015, at 9 a.m. Central European Time |
|
Where: |
BIO-Europe 2015 Level 0, Room 2 |
|
Contact: |
Kimberly Stoddard, kimberly@townsendteam.com, +1 (415) 806-5793 |
About CardioCell LLC
Founded in San Diego, California, in 2013, CardioCell LLC is a global biotechnology company that explores therapeutic applications of unique, patented, ischemia-tolerant mesenchymal stem cells manufactured under cGMP conditions. CardioCell is a subsidiary of Stemedica Cell Technologies Inc., a global biotechnology company that manufactures adult allogeneic stem cells. The company’s technology is based on more than 30 years of research and clinical experience conducted by scientists and physicians in the United States, Europe and the former Soviet Union. CardioCell therapies offer a unique, proprietary technology based on the expansion of cells in constant hypoxia, which provides critical benefits in terms of safety, efficacy and scalability. The company has an exclusive, worldwide license from Stemedica to explore therapeutic indications for unmet cardiovascular needs, such as acute myocardial infarction (AMI), chronic heart failure (CHF) and peripheral artery disease (PAD). For more information, visit www.stemcardiocell.com.